Intriguingly, in the general cancer population, high instead of low platelet count has been identified as a risk predictor for VTE.50, 128This may be due to the fact that glioblastoma patients exhibit increased expression levels of podoplanin, which induces platelet aggregation and, consequently, platelet consumption.69This finding underlines the tumor-specific biology in brain cancer patients and further warrants a VTE risk assessment model for this specific population. This evidence concerns the gene PDPN and glioblastoma.